[1]胡端凤,罗正辉,李清芳.尿毒清颗粒联合非布司他片治疗高血压肾病合并高尿酸血症的临床研究[J].医学信息,2021,34(23):62-65.[doi:10.3969/j.issn.1006-1959.2021.23.017]
　HU Duan-feng,LUO Zheng-hui,LI Qing-fang.Clinical Study on Niaoduqing Granules Combined with Febuxostat Tablets in Treatment of Hypertensive Nephropathy Complicated with Hyperuricemia[J].Medical Information,2021,34(23):62-65.[doi:10.3969/j.issn.1006-1959.2021.23.017]
点击复制

尿毒清颗粒联合非布司他片治疗高血压肾病合并高尿酸血症的临床研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年23期
页码:
62-65
栏目:
论著
出版日期:
2021-12-01

文章信息/Info

Title:
Clinical Study on Niaoduqing Granules Combined with Febuxostat Tablets in Treatment of Hypertensive Nephropathy Complicated with Hyperuricemia
文章编号:
1006-1959（2021）23-0062-04
作者:
胡端凤; 罗正辉; 李清芳
（上犹县人民医院肾内科，江西 上犹 341200）
Author(s):
HU Duan-feng; LUO Zheng-hui; LI Qing-fang
(Department of Nephrology,Shangyou County People’s Hospital,Shangyou 341200,Jiangxi,China)
关键词:
尿毒清颗粒; 非布司他片; 高血压; 肾病; 高尿酸血症
Keywords:
Niaoduqing granules; Febustamide tablets; Hypertension; Nephropathy; Hyperuricemia
分类号:
R589.7；R544.1
DOI:
10.3969/j.issn.1006-1959.2021.23.017
文献标志码:
A
摘要:
目的 研究尿毒清颗粒联合非布司他片治疗高血压肾病合并高尿酸血症的临床疗效。方法 选取2020年6月-2021年7月在我院诊治的90例高血压肾病合并高尿酸血症患者为研究对象，采用随机数字表法分为观察组、对照A组、对照B组，各30例。对照组A组采用尿毒清颗粒治疗，对照组B组采用非布司他片治疗，观察组采用尿毒清颗粒联合非布司他片治疗，比较三组治疗总有效率、血压（收缩压、舒张压）、内皮细胞功能指标[一氧化氮（NO）、内皮素－1（ET-1）]、血脂指标[低密度脂蛋白胆固醇（LDL-C）、甘油三脂（TG）、总胆固醇（TC）]、RAS活性相关指标[卧位血浆肾素活性（PRA）,血管紧张素Ⅱ（AngⅡ）]、尿酸水平。结果 观察组治疗总有效率高于对照A组、对照B组，差异有统计学意义（P＜0.05）；三组治疗后收缩压、舒张压低于治疗前，且观察组低于对照A组、对照B组，差异有统计学意义（P＜0.05）；三组治疗后NO高于治疗前、ET-1低于治疗前，且观察组NO低于对照A组、对照B组，ET-1高于对照A组、对照B组，差异有统计学意义（P＜0.05）；三组治疗后LDL-C、TG、TC低于治疗前，且观察组低于对照A组、对照B组，差异有统计学意义（P＜0.05）；三组治疗后卧位PRA、AngⅡ低于治疗前，且观察组低于对照A组、对照B组，差异有统计学意义（P＜0.05）；三组治疗后尿酸水平低于治疗前，且观察组低于对照A组、对照B组，差异有统计学意义（P＜0.05）。结论 尿毒清颗粒联合非布司他片治疗高血压肾病合并高尿酸血症疗效确切，可有效降低血压及血脂指标，改善血管内皮功能，降低RAS系统活性，具有应用有效性。
Abstract:
Objective To study the clinical efficacy of Niaoduqing Granules combined with Febuxostat Tablets in the treatment of hypertensive nephropathy with hyperuricemia.Methods A total of 90 patients with hypertensive nephropathy complicated with hyperuricemia who were treated in our hospital from June 2020 to July 2021 were selected as the research objects. They were randomly divided into observation group, control group A and control group B, with 30 cases in each group. The control group A was treated with Niaoduqing granules, the control group B was treated with febuxostat tablets, and the observation group was treated with Niaoduqing granules combined with febuxostat tablets. The total effective rate, blood pressure (systolic and diastolic blood pressure), endothelial cell function indexes [nitric oxide (NO), endothelin-1 (ET-1)], blood lipid indexes [low density lipoprotein cholesterol (LDL-C), triglyceride (TG), total cholesterol (TC)], RAS activity related indexes [supine plasma renin activity (PRA), angiotensin Ⅱ (AngⅡ)] and uric acid levels were compared among the three groups.Results The total effective rate of the observation group was higher than that of the control group A and the control group B, and the difference was statistically significant (P<0.05). The systolic blood pressure and diastolic blood pressure of the three groups after treatment were lower than those before treatment, and the observation group was lower than the control group A and the control group B, the difference was statistically significant (P<0.05). NO in three groups after treatment was higher than before treatment, ET-1 was lower than before treatment, NO in observation group was lower than control group A and control group B, ET-1 was higher than control group A and control group B, the difference was statistically significant (P<0.05). LDL-C, TG and TC in the three groups after treatment were lower than those before treatment, and those in the observation group were lower than the control group A and the control group B, the difference was statistically significant (P<0.05). The PRA and AngⅡ in the supine position of the three groups after treatment were lower than those before treatment, and the observation group was lower than the control group A and the control group B, the difference was statistically significant (P<0.05). The levels of uric acid in the three groups after treatment were lower than those before treatment, and the observation group was lower than the control group A and the control group B, the difference was statistically significant (P<0.05).Conclusion Niaoduqing granules combined with febuxostat tablets is effective in the treatment of hypertensive nephropathy with hyperuricemia, which can effectively reduce blood pressure and blood lipid indexes, improve vascular endothelial function, and reduce RAS system activity.

参考文献/References:

[1]马圣庭,刘斌,赵成军,等.缬沙坦联合氨氯地平治疗高血压合并肾功能不全患者的疗效比较[J].心脑血管病防治,2016,16(3):215-217.[2]封锐,胡元会.老年高血压病人尿酸水平与肾功能损伤及RAAS系统相关性研究[J].中西医结合心脑血管病杂志,2017,15(1):11-13.[3]Mallat SG,Al Kattar S,Tanios BY,et al.Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association[J].Curr Hypertens Rep,2016,18(10):74.[4]Baek CH,Kim H,Yang WS,et al.Efficacy and Safety of Febuxostat in Kidney Transplant Patients[J].Exp Clin Transplant,2018,16(4):401-406.[5]何志红,易建伟,袁峰,等.非布司他治疗尿酸性肾病的临床疗效观察[J].现代医院,2016,16(8):1260-1263.[6]卞志翔,朱士建,陈佩华.尿毒清颗粒联合非布司他片治糖尿病肾病合并高尿酸血症的疗效观察[J].兰州大学学报(医学版),2018,44(4):53-57.[7]黄玮,詹锋,林书典,等.痛风伴慢性肾脏病3-4 期患者尿酸达标治疗的临床研究[J].新医学,2017,48(6):410-414.[8]Zhang S,Wang Y,Cheng J,et al.Hyperuricemia and Cardiovascular Disease[J].Curr Pharm Des,2019,25(6):700-709.[9]余雪清,陈崴.中国慢性肾脏病患者合并高尿酸血症诊治专家共识[J].中华肾脏病杂志,2017,33(6):463-469.[10]商雪莹,邓霖,宋雨凌,等.苯溴马隆与非布司他在治疗2型糖尿病伴高尿酸血症的获益及安全性[J].实用药物与临床,2017,20(4):402-405.[11]侯小丽,吴述光,邱伟.非布司他治疗2型糖尿病肾病合并高尿酸血症的临床疗效[J].湘南学院学报,2017(4):41-43.[12]程锦绣,郝军荣,王琳琳,等.尿毒清颗粒对慢性肾衰竭腹膜透析大鼠生存质量及TGF-β1/Smad通路表达的影响[J].实用医学杂志,2018,34(5):725-728.[13]张洪源,林小堃.高通量血液透析联合尿毒清对老年终末期肾病患者细胞免疫的影响[J].实用医学杂志,2018,34(2):273-276.[14]张晓洁,姜林娣.尿酸代谢异常与慢性炎症的新认识[J].中华医学杂志,2018,98(13):963-964.[15]龚铭,匡永东,潘嘉西,等.尿毒清颗粒合并氯沙坦治疗高血压合并高尿酸血症的临床研究[J].中华全科医学,2017,15(7):1105-1108.[16]Webster AC,Nagler EV,Morton RL,et al.Chronic Kidney Disease[J].Lancet,2017,389(10075):1238-1252.[17]Petreski T,Bevc S,Ekart R,et al.Hyperuricemia and long-term survival in patients with chronic kidney disease undergoing hemodialysis[J].Clin Nephrol,2017,88(13):69-72.[18]金盛峰,吕华军,于路.非布司他联合苯磺酸氨氯地平治疗高血压合并高尿酸血症的效果[J].广东医学,2019,40(10):1476-1479.[19]宋柳全,谭焕原,谢宝超,等.非布司他在慢性肾脏合并高尿酸血症治疗中的应用价值分析[J].山东医药,2019,59(14):54-56.[20]王惠芳,张伟,李宁,等.非布司他治疗慢性肾脏病 3-5 期伴高尿酸血症患者的疗效分析及对肾功能的影响[J].中华高血压杂志,2018,26(9):900.

相似文献/References:

[1]吴 飞,余 路.尿毒清颗粒及前列地尔联合丹参酮治疗糖尿病肾病的疗效[J].医学信息,2019,32(13):153.[doi:10.3969/j.issn.1006-1959.2019.13.048]
　WU Fei,YU Lu.Therapeutic Effect of Urinary Granules and Alprostadil Combined with Tanshinone on Diabetic Nephropathy[J].Medical Information,2019,32(23):153.[doi:10.3969/j.issn.1006-1959.2019.13.048]
[2]李含阳,张 玉,于 莹.非布司他片治疗痛风伴高尿酸血症的临床研究及其对炎性因子IL-1β和NALP3水平的影响[J].医学信息,2023,36(10):124.[doi:10.3969/j.issn.1006-1959.2023.10.027]
　LI Han-yang,ZHANG Yu,YU Ying.Clinical Study of Febuxostat Tablets in the Treatment of Gout with Hyperuricemia and its Effect on the Levels of Inflammatory Factors IL-1β and NALP3[J].Medical Information,2023,36(23):124.[doi:10.3969/j.issn.1006-1959.2023.10.027]

更新日期/Last Update: 1900-01-01